What is Besponsa (inotuzumab ozogamicin)?
Besponsa is a prescription cancer medicine used to treat certain adults with relapsed or refractory acute lymphoblastic leukemia (ALL) that is B-cell lineage (often described as B-cell ALL). The active drug is inotuzumab ozogamicin. [1]
What does Besponsa treat, and who is it for?
It is used in adults with relapsed or refractory B-cell ALL. [1]
How is Besponsa given?
Besponsa is given as an intravenous (IV) infusion by healthcare professionals. [1]
What are the common side effects people ask about?
Common side effects include liver-related effects and low blood counts (such as neutropenia), among others reported for this treatment. [1]
What safety concerns are most important with Besponsa?
A key safety issue is liver toxicity, including an FDA-labeled warning about a serious liver problem called sinusoidal obstruction syndrome (SOS)/veno-occlusive disease in some patients. [1]
How does Besponsa work?
Besponsa is an antibody-drug conjugate: it targets a specific marker on leukemia cells (CD22) and delivers a chemotherapy-like payload into the cancer cells. [1]
Is Besponsa the same as other ALL antibody drugs?
Besponsa is specifically inotuzumab ozogamicin (targeting CD22 as an antibody-drug conjugate). Other ALL targeted therapies use different targets and different drugs, such as blinatumomab (CD19) or CAR-T therapies, so they are not interchangeable. [1]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115